Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125666271 | 12566627 | 1 | I | 20160308 | 20160712 | 20160718 | 20160718 | EXP | IT-MINISAL02-366815 | IT-DSJP-DSE-2016-124236 | DAIICHI | 0.00 | Y | 0.00000 | 20160718 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125666271 | 12566627 | 1 | PS | OLMESARTAN MEDOXOMIL. | OLMESARTAN MEDOXOMIL | 1 | Oral | 20 MG, QD | 1360 | MG | Y | 21286 | 20 | MG | TABLET | QD | |||
| 125666271 | 12566627 | 2 | SS | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 10 MG, QD | 130 | MG | 0 | 10 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125666271 | 12566627 | 1 | Hypertension |
| 125666271 | 12566627 | 2 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125666271 | 12566627 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125666271 | 12566627 | Syncope |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125666271 | 12566627 | 1 | 20160101 | 20160308 | 0 | |
| 125666271 | 12566627 | 2 | 20160225 | 20160308 | 0 |